As my video preview below explains, studies report that Cannabidiol CBD offers relief from Parkinson’s symptoms. Annual Parkinsons Recovery surveys also report success with reversing Parkinson’s symptoms when taking CBD oil. It is one of the most frequently listed therapies reported to be useful to members of the Parkinsons Recovery audience.

CBD stands for “cannabidiol oil”. It is extracted from either the Hemp plant or the Marijuana plant. Using CBD allows the medical benefits of medical marijuana without the high that is associated with THC. CBD in itself has no psychedelic properties and is considered safe for consumption
About Alovea Entourage Cannabidiol CBD
Alovea Entourage contain plant-derived cannabinoids, distinct from endocannabinoids that are produced in the body and synthetic cannabinoids. It includes Acemannan, an extract from the Aloe plant, to help the body’s management of mood, memory, sleep and joint health.
SYMBIOTIC IMMUNE SUPPORT
There are many products that have been formulated with additional ingredients to provide support for specific benefits like improved sleep, mood and joint health. One of the most profound impacts has come from the addition of immune modulating aloe vera Acemannan.
Combining the immune modulating fractions of Acemannan with high quality CBD hemp oil provides a symbiotic impact (1 + 1 = 4) that can dramatically enhance overall immune support.
PATENT-PENDING FORMULA INCLUDES:
- Organic Broad Spectrum Hemp Oil
- Super critical CO2 extraction
- Each batch tested to ensure 0.0% THC
- Absorption increased by 5-7 times over other hemp oil products with water compatible nanotechnology
- Enhanced Entourage Effect through proprietary terpene blend
- Symbiotic effect with the highest rated immune modulating Alovéa AE (Acemannan Extract)
- Wonderful cinnamon and tropical flavors!
Recent CBD (Cannabidiol) Research Studies
Clinical research on CBD (cannabidiol) includes studies of anxiety, cognition, movement disorders, and pain. Abstracts of recent studies are included below.
Pharmaceuticals (Basel). 2026 Feb 17;19(2):330. Cannabidiol in Neurology: Current Insights and Translational Perspectives
Abstract
Cannabidiol (CBD) is one of the most studied compounds of Cannabis sativa and has attracted significant interest due to its therapeutic and beneficial properties, which have been confirmed in numerous preclinical and clinical studies over the last few years.
A great advantage of CBD over the other widely known Cannabis sativa ingredient, ?-9-tetrahydrocannabinol (THC), is that CBD does not exert intoxicating and psychoactive effects, making it an attractive candidate for therapeutic applications in neurological disorders.
CBD has been shown to exert antioxidant, analgesic, anti-inflammatory, and neuroprotective effects, with therapeutic potential for various neurological conditions. To date, the only drug that consists solely of highly purified CBD is Epidiolex, which is used in the management of severe forms of epilepsy such as Dravet syndrome and Lennox-Gastaut syndrome. Another legal medication containing CBD (albeit with the addition of THC) is Sativex, used to alleviate spasticity in multiple sclerosis.
Besides epilepsy, preclinical data suggest that CBD alone may be potentially beneficial in treating chronic pain, multiple sclerosis, Alzheimer’s and Parkinson’s diseases, or stroke.
The safety profile of CBD is generally considered favorable, as the most commonly reported adverse effects are mild (e.g., somnolence, diarrhea).
Cannabis Cannabinoid Res. 2026 Feb;11(1):11-29. Unveiling Neurological Benefits: A Review of Hemp Leaf, Flower, Seed Oil Extract, and Their Phytochemical Properties in Neurological Disorders
Abstract
Neurological disorders such as epilepsy, Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis present significant global health care challenges, with complex pathophysiology and limited therapeutic options that often carry substantial side effects.
Hemp-derived compounds, particularly from Cannabis sativa seeds, leaves, and flowers, have gained attention for their potential neuroprotective properties. This review aims to synthesize the current evidence surrounding the therapeutic benefits of hemp-derived compounds, focusing on their bioactive phytochemical profiles, mechanisms of action, and therapeutic efficacy in treating neurological disorders.
A comprehensive review of pre-clinical and clinical studies was conducted, analyzing the phytochemical composition of hemp extracts, including cannabinoids (such as cannabidiol, CBD), terpenes, flavonoids, and polyunsaturated fatty acids. We explored their mechanisms of action through interactions with the endocannabinoid system, neurotransmitter receptors, inflammatory pathways, and oxidative stress mechanisms.
The review highlights the therapeutic potential of hemp-derived extracts in mitigating various neurological conditions. Pre-clinical and clinical studies have demonstrated their efficacy in reducing seizure frequency in epilepsy, protecting dopaminergic neurons in Parkinson’s disease, alleviating neuroinflammation and oxidative stress in Alzheimer’s disease, and promoting remyelination in multiple sclerosis.
The entourage effect, where cannabinoids, terpenes, and flavonoids work synergistically, enhances these therapeutic effects. Innovations in extraction technologies have optimized yield and preserved bioactivity, further enhancing clinical relevance.
Hemp-derived compounds exhibit significant neuroprotective and therapeutic potential for managing neurological disorders.
******
J Clin Sleep Med. 2025 Jan 1;21(1):69-80. Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study
Abstract
Study objectives: Cannabidiol (CBD) is increasingly used as a health supplement, though few clinical studies have demonstrated benefits. The primary objective of this study was to evaluate the effects of an oral CBD-terpene formulation on sleep physiology in individuals with insomnia.
Methods: In this double-blind, placebo-controlled, randomized clinical trial, 125 individuals with insomnia received an oral administration of CBD (300 mg) and terpenes (1 mg each of linalool, myrcene, phytol, limonene, ?-terpinene, ?-terpineol, ?-pinene, and ?-caryophyllene) for ? 4 days/wk over 4 weeks using a crossover design. The study medication was devoid of ?9-tetrahydrocannabinol. The primary outcome measure was the percentage of time participants spent in the combination of slow-wave sleep (SWS) and rapid eye movement (REM) sleep stages, as measured by a wrist-worn sleep-tracking device.
Results: This CBD-terpene regimen marginally increased the mean nightly percentage of time participants spent in SWS + REM sleep compared to the placebo (mean [standard error], 1.3% [0.60%]; 95% confidence interval, 0.1-2.5%; P = .03).
More robust increases were observed in participants with low baseline SWS + REM sleep, as well as in day sleepers. For select participants, the increase in SWS + REM sleep averaged as much as 48 minutes/night over a 4-week treatment period. This treatment had no effect on total sleep time, resting heart rate, or heart rate variability, and no adverse events were reported.
Conclusions: Select CBD-terpene ratios may increase SWS + REM sleep in some individuals with insomnia and may have the potential to provide a safe and efficacious alternative to over-the-counter sleep aids and commonly prescribed sleep medications.
******
J Obstet Gynaecol Can. 2025 Jul;47(7):102839. Cannabidiol Use and Perceptions of Effectiveness in Women With Chronic Pelvic Pain
Abstract
Objectives: To investigate cannabidiol (CBD) use in women with chronic pelvic pain and nociplastic pain, as represented by a diagnosis of fibromyalgia, including impact on pain and associated symptoms, substitutions for other medications, and side effects.
Methods: This was a cross-sectional study using data derived from an online survey distributed through the National Fibromyalgia Association between April and May of 2020. This secondary analysis was limited to participants with concurrent chronic pelvic pain diagnoses. Participants were asked about their history of CBD use and sub-grouped by use patterns.
Results: Of 1382 included participants, 501 (36.3%) were in the “Never Use” group, 404 (29.2%) were in the “Past Use” but not “Current Use” group and 477 (34.5%) were in the “Current Use” group. Of 477 participants in the “Current Use” group, 80.9% (n = 386) reported pain improvement. The most common indications for current CBD use were pain, insomnia, and anxiety. Participants who reported pain improvement were more likely to report improved sleep (P < 0.001), anxiety (P < 0.001), depression (P = 0.001), fatigue (P < 0.001), overall health (P < 0.001), and substitution of CBD for at least 1 other medication (P = 0.003) than those who reported no pain improvement. About half of the participants reported side effects, most of which were minor with the most common being drowsiness (n = 138, 29%).
Conclusions: Two-thirds of participants with concurrent chronic pelvic pain and fibromyalgia have used CBD. Improved pain with CBD use correlated with improvement in other symptom domains, such as sleep, mood, fatigue, and overall health. A large proportion of those using CBD reported substituting it for higher-risk medications.
Cannabis Cannabinoid Res. 2023 Oct;8(5):716-730.Cannabinoids in Treating Parkinson’s Disease Symptoms: A Systematic Review of Clinical Studies
Abstract
Background: Parkinson’s disease (PD) is a serious neurodegenerative condition impacting many individuals worldwide. There is a need for new non-invasive treatments of PD. Cannabinoids in the form of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may offer utility as treatment, and our objective was hence to conduct a systematic review regarding the clinical evidence for the efficacy and safety of cannabinoids in treating PD.
Methods: Screening, data extraction, and quality assessments were all conducted by multiple reviewers, with discrepancies resolved by consensus.
Results: After conducting searches in 4 different databases, 673 articles were screened. Thirteen articles were deemed eligible for inclusion in this review. It was shown that cannabis, CBD, and nabilone (a synthetic form of THC) were capable of consistently improving motor symptoms more than a placebo. All treatments improved various non-motor symptoms, particularly with cannabis improving pain intensity, and CBD improving psychiatric symptoms in a dose-dependent manner. Adverse effects were usually minor, and, in the case of CBD, rare (except at very high doses).
Conclusion: Cannabinoids have been shown to safely offer important potential in treating motor symptoms in PD and some non-motor symptoms.
Robert Rodgers PhD
Founder 2004
Parkinsons Recovery ®
https://www.parkinsonsrecovery.com
robert@parkinsonsrecovery.com




Leave a Reply